Evidence map›Paper›PMID 31531059›Full record

ArticleIranian journal of pharmaceutical research : IJPR2019

Characterization of Novel Fragment Antibodies Against TNF-alpha Isolated Using Phage Display Technique.

Ali Akbar Alizadeha, Maryam Hamzeh-Mivehroud, Elnaz Haddad, Nazanin Haddad, Mehdi Sharifi, Samin Mohammadi, Samira Pourtaghi-Anvarian, Siavoush Dastmalchi

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of pharmaceutical research : IJPR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Ali Akbar AlizadehaBiotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Maryam Hamzeh-MivehroudBiotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Elnaz HaddadSchool of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Nazanin HaddadSchool of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Mehdi SharifiSchool of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Samin MohammadiSchool of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Samira Pourtaghi-AnvarianSchool of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Siavoush DastmalchiBiotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Tabriz University of Medical Sciences · IRBiotechnology Research Center · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor necrosis factor alpha (TNF-α) is an inflammatory cytokine which plays crucial roles in pathogenesis of inflammatory diseases. The current study aimed to investigate the binding abilities of I44 and I49 domain antibodies to TNF-α. The dAbs were expressed in bacterial expression system and purified by affinity chromatography using Ni-sepharose column. The expression and purity of the proteins were evaluated using western blotting and SDS-PAGE techniques, respectively. ELISA experiment showed that I44 and I49 dAbs bind to TNF-α with the binding constants (K

Indexed as

Domain antibodiesMolecular dockingPhage displayRecombinant protein productionTNF-α

Identifiers

PMID31531059
PMCPMC6706722
OpenAlexW2936466351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.